Rachel Isaksson Vogel1,2, Lori G Strayer3, Leah Engelman4, Heather H Nelson3,4, Anne H Blaes3,5, Kristin E Anderson3,4, DeAnn Lazovich3,4. 1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, 420 Delaware Street SE, MMC 395, Minneapolis, MN, 55455, USA. isak0023@umn.edu. 2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. isak0023@umn.edu. 3. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. 4. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA. 5. Division of Hematology and Oncology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Abstract
PURPOSE: Little is known about specific concerns facing long-term melanoma survivors. The goal of this study was to compare quality of life (QOL) and mental health between long-term melanoma survivors and population controls. METHODS: Participants from a previously conducted case-control study of risk factors for melanoma were recruited for a cross-sectional survey. Generic QOL and emotional health were measured using the SF-36 and Hospital Anxiety and Depression Scale questionnaires. A total of 724 melanoma survivors and 660 controls participated. Most melanoma survivors had stage I disease (85.6%); mean time from diagnosis was 9.6 ± 1.0 years. Comparisons of QOL measures between melanoma survivors and controls were conducted using regression models, adjusting for potential confounders. RESULTS: Melanoma survivors, compared to controls, reported statistically significant but only slightly higher physical functioning and bodily pain QOL subscale scores than controls and otherwise similar QOL as measured by the remaining six SF-36 subscale scores. Prevalence of anxiety (18.1% vs. 19.3%, adjusted OR = 1.00 (0.74, 1.36); p = 1.00) and depression (7.2% vs. 9.8%, adjusted OR = 0.74 (0.48, 1.16); p = 1.00) were similar between melanoma survivors and controls. CONCLUSION: Long-term early stage melanoma survivors report similar general QOL and mental health compared to population controls. Further research is needed to identify concerns more specific to melanoma.
PURPOSE: Little is known about specific concerns facing long-term melanoma survivors. The goal of this study was to compare quality of life (QOL) and mental health between long-term melanoma survivors and population controls. METHODS:Participants from a previously conducted case-control study of risk factors for melanoma were recruited for a cross-sectional survey. Generic QOL and emotional health were measured using the SF-36 and Hospital Anxiety and Depression Scale questionnaires. A total of 724 melanoma survivors and 660 controls participated. Most melanoma survivors had stage I disease (85.6%); mean time from diagnosis was 9.6 ± 1.0 years. Comparisons of QOL measures between melanoma survivors and controls were conducted using regression models, adjusting for potential confounders. RESULTS:Melanoma survivors, compared to controls, reported statistically significant but only slightly higher physical functioning and bodily pain QOL subscale scores than controls and otherwise similar QOL as measured by the remaining six SF-36 subscale scores. Prevalence of anxiety (18.1% vs. 19.3%, adjusted OR = 1.00 (0.74, 1.36); p = 1.00) and depression (7.2% vs. 9.8%, adjusted OR = 0.74 (0.48, 1.16); p = 1.00) were similar between melanoma survivors and controls. CONCLUSION: Long-term early stage melanoma survivors report similar general QOL and mental health compared to population controls. Further research is needed to identify concerns more specific to melanoma.
Entities:
Keywords:
Cancer survivorship; Melanoma; Quality of life; SF-36
Authors: Rachel Isaksson Vogel; Lori G Strayer; Leah Engelman; Heather H Nelson; Anne H Blaes; Kristin E Anderson; DeAnn Lazovich Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-02 Impact factor: 4.254
Authors: Cynthia Holterhues; Darren Cornish; Lonneke Veronique van de Poll-Franse; Gertruud Krekels; Frans Koedijk; Danielle Kuijpers; Jan Willem Coebergh; Tamar Nijsten Journal: Arch Dermatol Date: 2011-02
Authors: Sarah Heinze; Friederike Egberts; Susanne Rötzer; Matthias Volkenandt; Wolfgang Tilgen; Ruthild Linse; Jörg Boettjer; Thomas Vogt; Konstanze Spieth; Thomas Eigentler; Norbert H Brockmeyer; Axel Hinzpeter; Axel Hauschild; Martin Schaefer Journal: J Immunother Date: 2010-01 Impact factor: 4.456
Authors: Ashley E Stenzel; Jonathan Miller; Shernan G Holtan; Katherine Brown; Rehana L Ahmed; DeAnn Lazovich; Rachel I Vogel Journal: Arch Dermatol Res Date: 2022-02-24 Impact factor: 3.033
Authors: Rachel I Vogel; Broderick Yoerg; Patricia I Jewett; Nathan Rubin; Megan Olson; Ashley E Stenzel; Rehana L Ahmed; DeAnn Lazovich Journal: Support Care Cancer Date: 2021-02-12 Impact factor: 3.359
Authors: Daan Brandenbarg; Saskia W M C Maass; Olaf P Geerse; Mariken E Stegmann; Charlotte Handberg; Maya J Schroevers; Saskia F A Duijts Journal: Eur J Cancer Care (Engl) Date: 2019-05-14 Impact factor: 2.328